The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Company Receives Award Notice for Development of Next-Generation High-Energy-Density Batteries for Critical Space Missions CARSON CITY, NV, UNITED STATES, January 6, 2026 /EINPresswire.com/ — NexTech ...

Inimmune Corporation ("Inimmune"), a clinical-stage biotechnology company focused on developing innovative immunotherapies, ...

The Central Terminal Restoration Corporation has released a new video that details the current progress of Phase II of the ...

Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...

The General Services Administration has launched the second phase of the One Acquisition Solution for Integrated Services Plus, or OASIS+, contract program, adding five new service domains as part of ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Winston-Salem's Innovation Quarter enjoyed a year of expansion in 2025. Plans are now in place to enter Phase II of its ...